RecruitingNot Applicable

Digital Mindfulness for Young Adults With Type 1 Diabetes

United States10 participantsStarted 2026-02-04

Plain-language summary

The purpose of this research study is to test a mindfulness app called Calm Health among young adults with type 1 diabetes or other absolute insulin deficiency diabetes. Mindfulness is the practice of being aware of your thoughts and feelings in the moment without judgment or negative reaction. All participants will receive mindfulness guidance and personalized feedback about the relationship among your mindfulness, blood sugar, stress, and sleep.

Who can participate

Age range18 Years – 30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Receiving diabetes care at Yale New Haven Children's Hospital or Yale New Haven Hospital.
✓. Sign and date informed consent form we will provide
✓. Willingness to complete procedures and availability for duration of the study
✓. Aged 18-30 years
✓. Diagnosed with type 1 diabetes (T1D) or other absolute insulin deficiency diabetes (latent autoimmune diabetes of adulthood, diabetes secondary to pancreatitis) for at least 1 year.
✓. User of a continuous glucose monitor (CGM) in your routine clinical care for at least the past 2 weeks.
✓. Able to use a smartphone.
✓. Able to read and write English.

Exclusion criteria

✕. Current meditation or mindfulness practice meeting or exceeding the study's recommended schedule
✕. Current severe untreated psychiatric illness (e.g., bipolar disorder, schizophrenia, major depression, panic disorder, borderline personality disorder, organic mood or mental disorders) or active suicidal ideation
✕. New or unstable psychopharmaceutical treatment in past 2 months.
✕. Current or planned pregnancy during study period.

What they're measuring

Mindfulness app usage

Timeframe: 6 weeks

Trial details

NCT IDNCT07062887

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09

Contact for this trial

Laura M Nally, MD

203-785-5831 laura.nally@yale.edu

View on ClinicalTrials.gov More Type 1 Diabetes (T1D) trials